Financial Snapshot

Revenue
$9.600M
TTM
Gross Margin
-224.79%
TTM
Net Earnings
-$97.54M
TTM
Current Assets
$85.15M
Q4 2023
Current Liabilities
$31.37M
Q4 2023
Current Ratio
271.48%
Q4 2023
Total Assets
$670.3M
Q4 2023
Total Liabilities
$161.6M
Q4 2023
Book Value
$508.7M
Q4 2023
Cash
P/E
-11.05
Nov 29, 2024 EST
Free Cash Flow
-$75.87M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005
Revenue $7.501M $10.21M $7.456M $32.16M $16.72M $17.34M $2.412M $42.55M $19.76M $23.84M $29.52M $39.34M $18.99M $660.0K $650.0K $810.0K $1.320M $2.110M $380.0K
YoY Change -26.56% 36.99% -76.81% 92.3% -3.57% 618.95% -94.33% 115.31% -17.11% -19.24% -24.96% 107.16% 2777.27% 1.54% -19.75% -38.64% -37.44% 455.26%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005
Revenue $7.501M $10.21M $7.456M $32.16M $16.72M $17.34M $2.412M $42.55M $19.76M $23.84M $29.52M $39.34M $18.99M $660.0K $650.0K $810.0K $1.320M $2.110M $380.0K
Cost Of Revenue $27.73M $30.76M $32.72M $25.31M $15.36M $5.508M $12.07M $29.76M $23.78M $25.33M $21.48M $22.70M
Gross Profit -$20.23M -$20.54M -$25.26M $6.847M $1.364M $11.83M -$9.653M $12.79M -$4.022M -$1.490M $8.040M $16.64M
Gross Profit Margin -269.72% -201.13% -338.83% 21.29% 8.16% 68.24% -400.21% 30.05% -20.35% -6.25% 27.24% 42.3%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005
Selling, General & Admin $25.37M $27.21M $30.87M $25.61M $21.63M $21.91M $23.01M $22.50M $29.54M $23.50M $31.51M $28.92M $11.68M $3.140M $2.330M $2.360M $3.220M $2.800M $500.0K
YoY Change -6.75% -11.85% 20.53% 18.42% -1.29% -4.78% 2.25% -23.83% 25.7% -25.42% 8.96% 147.6% 271.97% 34.76% -1.27% -26.71% 15.0% 460.0%
% of Gross Profit 374.02% 1585.41% 185.13% 175.99% 391.92% 173.8%
Research & Development $27.19M $32.82M $51.54M $54.73M $58.36M $64.31M $58.91M $50.01M $62.65M $50.74M $44.20M $38.09M $15.10M $6.660M $5.250M $5.550M $3.600M $4.000M $570.0K
YoY Change -17.14% -36.33% -5.84% -6.21% -9.25% 9.16% 17.8% -20.17% 23.47% 14.8% 16.04% 152.25% 126.73% 26.86% -5.41% 54.17% -10.0% 601.75%
% of Gross Profit 799.37% 4278.59% 543.49% 391.18% 549.75% 228.91%
Depreciation & Amortization $1.462M $1.462M $1.475M $1.455M $1.455M $1.616M $80.00K
YoY Change 0.0% -0.88% 1.37% 0.0% -9.96%
% of Gross Profit 21.25% 106.67% 13.66%
Operating Expenses $27.19M $32.82M $65.12M $80.34M $87.83M $76.14M $80.52M $31.25M $87.77M $66.35M $69.64M $66.88M $26.79M $9.800M $7.580M $7.920M $6.820M $6.810M $1.160M
YoY Change -17.14% -49.61% -18.94% -8.53% 15.35% -5.44% 157.66% -64.4% 32.28% -4.72% 4.13% 149.65% 173.37% 29.29% -4.29% 16.13% 0.15% 487.07%
Operating Profit -$47.42M -$53.36M -$90.39M -$73.49M -$86.47M -$64.31M -$90.17M -$18.47M -$91.79M -$67.84M -$61.60M -$50.24M
YoY Change -11.13% -40.97% 22.99% -15.0% 34.45% -28.68% 388.34% -79.88% 35.31% 10.13% 22.61%

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005
Interest Expense $19.44M $16.91M -$14.47M -$14.47M -$11.91M -$1.668M -$43.00K -$1.126M $10.48M -$3.650M $0.00 -$1.450M -$3.870M -$2.100M -$1.900M -$1.350M -$1.500M -$360.0K
YoY Change 15.01% -216.85% -0.01% 21.47% 614.15% 3779.07% -96.18% -110.75% -387.07% -100.0% -62.53% 84.29% 10.53% 40.74% -10.0% 316.67%
% of Operating Profit
Other Income/Expense, Net $0.00 -$9.311M -$8.099M -$1.660M $0.00 -$130.0K
YoY Change -100.0% 14.96% 387.89% -100.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

No data

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005
Pretax Income -$82.10M -$91.59M -$99.63M -$87.36M -$98.75M -$65.98M -$90.22M -$90.82M -$96.24M -$74.27M -$61.60M -$50.24M $90.98M -$13.01M -$9.030M -$9.000M -$6.850M -$6.200M -$1.140M
YoY Change -10.36% -8.07% 14.05% -11.54% 49.68% -26.87% -0.67% -5.63% 29.59% 20.57% 22.61% -155.22% -799.31% 44.08% 0.33% 31.39% 10.48% 443.86%
Income Tax -$212.0K -$239.0K -$819.0K -$9.415M -$8.955M -$30.69M -$13.40M -$86.69M $0.00 $0.00 $1.630M $23.12M $1.610M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income 1.77%
Net Earnings -$81.89M -$91.35M -$98.81M -$77.94M -$89.80M -$35.29M -$76.82M -$4.127M -$96.24M -$74.28M -$63.23M -$73.36M $89.36M -$13.01M -$9.030M -$9.000M -$6.850M -$6.200M -$1.140M
YoY Change -10.35% -7.55% 26.78% -13.21% 154.46% -54.06% 1761.28% -95.71% 29.57% 17.48% -13.81% -182.09% -786.86% 44.08% 0.33% 31.39% 10.48% 443.86%
Net Earnings / Revenue -1091.71% -894.33% -1325.25% -242.38% -537.01% -203.51% -3184.7% -9.7% -487.04% -311.58% -214.19% -186.48% 470.56% -1971.21% -1389.23% -1111.11% -518.94% -293.84% -300.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.11 -$140.8K -$163.3K -$147.4K -$181.6K -$75.78K -$192.4K -$11.32K -$296.9K -$230.2K -$213.8K -$256.8K $388.4K -$91.63K -$71.97K -$78.02K -$63.71K -$65.64K -$15.78K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

No data

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005
Cash & Short-Term Investments $70.92M $60.05M $136.4M $128.9M $50.03M $37.61M $45.51M $80.93M $110.7M $185.2M $288.1M $211.6M $282.1M $27.70M $13.30M $13.50M $10.20M $5.800M $11.50M
YoY Change 18.1% -55.97% 5.78% 157.72% 33.0% -17.35% -43.77% -26.89% -40.23% -35.72% 36.15% -24.99% 918.41% 108.27% -1.48% 32.35% 75.86% -49.57%
Cash & Equivalents -$2.000K $13.00K -$49.00K $12.00K $21.00K $142.0K $37.54M $59.07M $89.58M $181.6M $280.9M $900.0K $600.0K $5.500M $800.0K $4.100M $10.20M $5.800M $11.50M
Short-Term Investments $250.0K $250.0K $208.1M $278.1M $22.10M $12.30M $8.700M
Other Short-Term Assets $3.742M $5.387M $7.004M $6.046M $8.436M $13.34M $14.61M $3.837M $7.787M $1.200M $4.100M $300.0K $200.0K $100.0K $100.0K $100.0K $0.00 $100.0K $0.00
YoY Change -30.54% -23.09% 15.85% -28.33% -36.77% -8.65% 280.68% -50.73% 548.92% -70.73% 1266.67% 50.0% 100.0% 0.0% 0.0% -100.0%
Inventory
Prepaid Expenses
Receivables $2.276M $2.224M $2.000M $678.0K $1.741M $6.711M $594.0K $702.0K $136.0K $0.00 $0.00 $2.200M $100.0K $100.0K $100.0K $0.00 $300.0K
Other Receivables $4.722M $2.179M $2.842M $896.0K $2.319M $43.41M $2.899M $3.352M $3.836M $5.800M $11.00M $8.700M $2.200M $300.0K $100.0K $100.0K $100.0K
Total Short-Term Assets $81.66M $69.84M $148.2M $136.5M $62.52M $101.1M $63.61M $88.82M $122.5M $192.1M $303.2M $222.8M $284.5M $28.20M $13.60M $13.70M $10.70M $6.000M $11.70M
YoY Change 16.93% -52.89% 8.55% 118.4% -38.14% 58.89% -28.39% -27.47% -36.25% -36.64% 36.09% -21.69% 908.87% 107.35% -0.73% 28.04% 78.33% -48.72%
Property, Plant & Equipment $6.491M $9.965M $12.14M $10.27M $826.0K $1.084M $1.814M $3.063M $4.398M $4.400M $2.500M $2.000M $700.0K $200.0K $200.0K $200.0K $100.0K $0.00 $0.00
YoY Change -34.86% -17.92% 18.2% 1143.46% -23.8% -40.24% -40.78% -30.35% -0.05% 76.0% 25.0% 185.71% 250.0% 0.0% 0.0% 100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.757M $1.758M $2.080M $1.871M $2.317M $2.321M $1.997M $1.966M $2.300M $0.00 $4.500M $7.500M $12.20M $6.500M $5.600M $4.000M
YoY Change -0.06% -15.48% 11.17% -19.25% -0.17% 16.22% 1.58% -14.52% -100.0% -40.0% -38.52% 87.69% 16.07% 40.0%
Other Assets $2.326M $1.930M $1.724M $1.838M $1.851M $1.888M $1.916M $2.343M $2.367M $2.800M $1.200M $3.600M $23.40M
YoY Change 20.52% 11.95% -6.2% -0.7% -1.96% -1.46% -18.22% -1.01% -15.46% 133.33% -66.67% -84.62%
Total Long-Term Assets $587.8M $592.3M $596.5M $597.1M $589.6M $591.4M $592.1M $595.2M $659.3M $655.9M $504.2M $514.4M $533.5M $5.000M $8.200M $12.90M $7.300M $6.200M $4.600M
YoY Change -0.77% -0.7% -0.09% 1.27% -0.3% -0.12% -0.52% -9.72% 0.52% 30.09% -1.98% -3.58% 10570.0% -39.02% -36.43% 76.71% 17.74% 34.78%
Total Assets $669.4M $662.1M $744.7M $733.6M $652.1M $692.4M $655.7M $684.0M $781.8M $848.0M $807.4M $737.2M $818.0M $33.20M $21.80M $26.60M $18.00M $12.20M $16.30M
YoY Change
Accounts Payable $20.15M $23.08M $19.60M $24.97M $13.06M $18.92M $21.81M $27.16M $28.24M $19.50M $19.00M $11.80M $3.300M $1.200M $900.0K $1.400M $400.0K $1.700M $200.0K
YoY Change -12.71% 17.76% -21.52% 91.21% -30.98% -13.23% -19.7% -3.85% 44.83% 2.63% 61.02% 257.58% 175.0% 33.33% -35.71% 250.0% -76.47% 750.0%
Accrued Expenses $2.013M $3.333M $4.195M $5.748M $4.231M $4.358M $3.811M $2.019M $4.600M $500.0K $400.0K $700.0K $100.0K $0.00 $100.0K $200.0K
YoY Change -39.6% -20.55% -27.02% 35.85% -2.91% 14.35% 88.76% 820.0% 25.0% -42.86% 600.0% -100.0% -50.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $10.01M $8.203M $55.97M $35.97M $14.01M
YoY Change 22.05% -85.34% 55.57% 156.83%
Total Short-Term Liabilities $41.98M $51.37M $94.27M $90.14M $44.33M $24.00M $36.67M $29.42M $48.41M $40.20M $46.20M $45.50M $33.00M $1.300M $1.000M $1.500M $600.0K $3.300M $1.700M
YoY Change -18.28% -45.51% 4.58% 103.34% 84.69% -34.54% 24.66% -39.23% 20.42% -12.99% 1.54% 37.88% 2438.46% 30.0% -33.33% 150.0% -81.82% 94.12%
Long-Term Debt $106.5M $98.70M $49.53M $63.34M $67.28M $59.40M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change 7.88% 99.28% -21.8% -5.85% 13.27%
Other Long-Term Liabilities $19.11M $15.02M $19.52M $30.06M $48.33M $42.96M $52.96M $63.75M $116.0M $119.1M $51.90M $65.70M $95.20M
YoY Change 27.22% -23.03% -35.08% -37.8% 12.51% -18.89% -16.93% -45.04% -2.62% 129.48% -21.0% -30.99%
Total Long-Term Liabilities $125.6M $113.7M $69.05M $93.40M $115.6M $102.4M $52.96M $63.75M $116.0M $119.1M $51.90M $65.70M $95.20M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change 10.44% 64.71% -26.08% -19.21% 12.95% 93.28% -16.93% -45.04% -2.62% 129.48% -21.0% -30.99%
Total Liabilities $167.6M $165.1M $163.3M $184.3M $171.1M $146.4M $138.9M $155.9M $313.8M $308.9M $231.5M $247.2M $265.1M $1.300M $1.000M $1.500M $600.0K $3.300M $1.700M
YoY Change 1.5% 1.09% -11.37% 7.72% 16.82% 5.41% -10.87% -50.33% 1.58% 33.43% -6.35% -6.75% 20292.31% 30.0% -33.33% 150.0% -81.82% 94.12%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

No data

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $1.0783 Billion

About MESOBLAST LTD

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 83 full-time employees. The company went IPO on 2004-12-16. The company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. The company is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. The company has established commercial partnerships in Europe and China for certain Phase III assets.

Industry: Biological Products, (No Diagnostic Substances) Peers: